Payment overview · 2025
General Payments
$1,387.92
68 reported records · 20 companies
Healthcare provider profile · identity verified
Sanjay M Chavda, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · HOPKINSVILLE, KY · NPI 1437124484
Verified facts
What the public records show
CMS Open Payments records show Sanjay M Chavda, MD received $1,387.92 in general payments during 2025 across 68 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Opsumit, Trelegy Ellipta.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Opsumit by this doctor in 2024.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UPTRAVI as an associated drug or biological on 21562 records involving 9341 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Uptravi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $350.50 | 25.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $279.97 | 20.2% | 18 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $142.58 | 10.3% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.63 | 5.2% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $68.93 | 5.0% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $61.69 | 4.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $53.75 | 3.9% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $44.82 | 3.2% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.89 | 2.8% | 2 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $38.38 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.07 | 2.7% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $36.51 | 2.6% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $30.15 | 2.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $28.86 | 2.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $26.16 | 1.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.26 | 1.5% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $16.23 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.06 | 1.0% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $13.85 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.63 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,387.92 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $262.41 | 6 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $219.91 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $216.64 | 3 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $196.33 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $174.09 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $68.93 | 4 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $61.69 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $60.06 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.03 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $44.82 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $38.89 | 2 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $38.38 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $38.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $38.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $38.38 | 1 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $30.15 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $28.86 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.19 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $7.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OPSUMIT opsumit |
2025 | Opsumit | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 167 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | UPTRAVI open payments reported associated product |
CMS Open Payments — General Payments 21562 supporting records · 9341 recipient NPIs · example record 1174163984 |
Uptravi · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
167 | 52 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 251 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 210 | 97 |
| Prednisone | Prednisone | 195 | 78 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 167 | 52 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 23 |
| Gabapentin | Gabapentin | 97 | 32 |
| Eliquis | Apixaban | 95 | 21 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 88 | 32 |
| Losartan Potassium | Losartan Potassium | 85 | 28 |
| Lisinopril | Lisinopril | 82 | 34 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 79 | 33 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 74 | 22 |
| Trazodone Hcl | Trazodone Hcl | 68 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 66 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 43 |
| Mirtazapine | Mirtazapine | 62 | 19 |
| Buspirone Hcl | Buspirone Hcl | 61 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 11 |
| Furosemide | Furosemide | 57 | 28 |
| Ozempic | Semaglutide | 56 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 56 | 15 |
| Omeprazole | Omeprazole | 50 | 17 |
| Jardiance | Empagliflozin | 49 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 47 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 12 |
| Azithromycin | Azithromycin | 39 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Carvedilol | Carvedilol | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Metformin Hcl | Metformin Hcl | 38 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 23 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | 11 |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Dupixent Pen | Dupilumab | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | 13 |
| Alprazolam | Alprazolam | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | 12 |
| Allopurinol | Allopurinol | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | 11 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ofev | Nintedanib Esylate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Uptravi | Selexipag | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Roflumilast | Roflumilast | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fasenra Pen | Benralizumab | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Opsumit | Macitentan | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Dayvigo | Lemborexant | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,387.92 · 68 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CHARTIS CATHETER, DUPIXENT, ENTRESTO, FARXIGA, FASENRA, GLASSIA, GVOKE HYPOPEN, Hillrom - Vest System Model 105 Home Care, INSPIRE, LEQVIO, NUCALA, OPSUMIT, OTEZLA, Ohtuvayre, PULMONX CHARTIS TABLET CONSOLE, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, Quviviq, REPATHA, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, Tyvaso, WINREVAIR, XOLAIR, YUPELRI, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error